Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

Ramesh K. Ramanathan, Donald L. Trump, Julie L. Eiseman, Chandra P. Belani, Sanjiv S. Agarwala, Eleanor G. Zuhowski, Jing Lan, Douglas M. Potter, S. Percy Ivy, Sakkaraiappan Ramalingam, Adam M. Brufsky, Michael K.K. Wong, Susan Tutchko, Merrill J. Egorin

Research output: Contribution to journalArticlepeer-review

185 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers'. Together they form a unique fingerprint.

Medicine & Life Sciences